FindTrial
Sign In

Risk Factors and Prediction Model of False-Negative Diagnosis in Repeated EUS-FNA/B of Pancreatic Solid Lesions Following Initial Non-diagnostic or Inconclusive Findings

Risk Factors and Prediction Model of False-Negative Diagnosis in Repeated EUS-FNA/B of Pancreatic Solid Lesions Following Initial Non-diagnostic or Inconclusive Findings

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113221
Enrollment
Unknown
Registered
2025-11-26
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid pancreatic lesions

Interventions

Observation group:None

Sponsors

Shanghai Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: All adult patients (=18 years old) who underwent rEUS-FNA/B for SPLs following previous nondiagnostic or inconclusive EUS-guided sampling were enrolled in the study.

Exclusion criteria

Exclusion criteria: Exclusion criteria were as following: 1) pancreatic cystic neoplasms; 2) extrapancreatic lesions, e.g., biliary tumor, retroperitoneal mass; 3) EUS-guided therapeutic procedure, e.g., radiopaque particle implantation; 4) loss to follow-up.

Design outcomes

Primary

MeasureTime frame
Influencing factors of false-negative results in ultrasound-guided fine-needle aspiration biopsy (EUS-FNA/B);Risk prediction model for false-negative results of endoscopic ultrasound-guided fine-needle aspiration and biopsy (EUS-FNA/B);—

Secondary

MeasureTime frame
The diagnostic accuracy of false-negative results for the repeated ultrasound-guided fine-needle aspiration biopsy procedure (EUS-FNA/B);—

Countries

China

Contacts

Public ContactKaixuan Wang

Shanghai Changhai Hospital

wangkaixuan224007@163.com+86 135 8567 3477

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026